0.7463
price down icon0.43%   -0.0032
pre-market  시장 영업 전:  .71   -0.0363   -4.86%
loading
전일 마감가:
$0.7495
열려 있는:
$0.7569
하루 거래량:
948.35K
Relative Volume:
0.47
시가총액:
$138.89M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-0.5112
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+6.72%
1개월 성능:
-0.76%
6개월 성능:
-26.83%
1년 성능:
-46.69%
1일 변동 폭
Value
$0.72
$0.78
1주일 범위
Value
$0.6728
$0.8297
52주 변동 폭
Value
$0.432
$1.5195

넥타테라퓨틱스 Stock (NKTR) Company Profile

Name
명칭
Nektar Therapeutics
Name
전화
(415) 482-5300
Name
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
직원
61
Name
트위터
@nektarnews
Name
다음 수익 날짜
2025-03-12
Name
최신 SEC 제출 서류
Name
NKTR's Discussions on Twitter

NKTR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NKTR
Nektar Therapeutics
0.7463 130.14M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-11 업그레이드 Jefferies Hold → Buy
2025-03-14 업그레이드 Oppenheimer Perform → Outperform
2025-01-08 개시 B. Riley Securities Buy
2024-12-10 개시 H.C. Wainwright Buy
2024-11-04 개시 Piper Sandler Overweight
2024-09-30 재개 BTIG Research Buy
2024-06-28 개시 Rodman & Renshaw Buy
2023-11-20 재개 JP Morgan Underweight
2023-11-09 업그레이드 TD Cowen Market Perform → Outperform
2023-05-10 업그레이드 Jefferies Underperform → Hold
2023-02-24 다운그레이드 Jefferies Hold → Underperform
2022-08-08 다운그레이드 JP Morgan Neutral → Underweight
2022-05-31 재개 Jefferies Hold
2022-04-18 다운그레이드 Goldman Neutral → Sell
2022-03-15 다운그레이드 Cowen Outperform → Market Perform
2022-03-15 다운그레이드 Mizuho Buy → Neutral
2022-03-14 다운그레이드 BTIG Research Buy → Neutral
2022-03-14 다운그레이드 BofA Securities Neutral → Underperform
2022-03-14 다운그레이드 Stifel Buy → Hold
2022-03-14 다운그레이드 William Blair Outperform → Mkt Perform
2022-03-09 업그레이드 Oppenheimer Perform → Outperform
2021-11-08 업그레이드 The Benchmark Company Hold → Buy
2021-09-10 개시 BofA Securities Neutral
2021-06-28 업그레이드 Stifel Hold → Buy
2021-05-18 재개 Goldman Neutral
2021-02-22 다운그레이드 The Benchmark Company Buy → Hold
2021-01-06 개시 Stifel Hold
2020-09-14 개시 JP Morgan Neutral
2020-06-10 다운그레이드 CFRA Hold → Sell
2020-05-12 재확인 H.C. Wainwright Neutral
2020-04-22 개시 The Benchmark Company Buy
2020-03-30 업그레이드 Goldman Sell → Neutral
2020-03-04 개시 Barclays Overweight
2020-02-03 업그레이드 Mizuho Neutral → Buy
2019-10-24 개시 Oppenheimer Perform
2019-10-08 다운그레이드 Goldman Buy → Sell
2019-08-09 다운그레이드 JP Morgan Overweight → Neutral
2019-08-09 다운그레이드 Jefferies Buy → Hold
2019-08-09 다운그레이드 Mizuho Buy → Neutral
2019-03-15 개시 SVB Leerink Mkt Perform
2018-12-13 개시 Goldman Buy
2018-06-11 다운그레이드 H.C. Wainwright Buy → Neutral
2018-06-04 재확인 H.C. Wainwright Buy
2018-04-20 개시 Seaport Global Securities Buy
2018-04-13 재개 Piper Jaffray Overweight
2018-04-06 재확인 Mizuho Buy
2018-04-02 재개 H.C. Wainwright Buy
모두보기

넥타테라퓨틱스 주식(NKTR)의 최신 뉴스

pulisher
Jun 04, 2025

Nektar Therapeutics Approves Reverse Stock Split - TipRanks

Jun 04, 2025
pulisher
May 30, 2025

Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 30, 2025
pulisher
May 29, 2025

Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 29, 2025
pulisher
May 28, 2025

Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com

May 28, 2025
pulisher
May 28, 2025

BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 28, 2025
pulisher
May 28, 2025

Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks

May 28, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st

May 23, 2025
pulisher
May 22, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World

May 22, 2025
pulisher
May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq

May 20, 2025
pulisher
May 16, 2025

Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN

May 16, 2025
pulisher
May 16, 2025

Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World

May 16, 2025
pulisher
May 16, 2025

What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World

May 16, 2025
pulisher
May 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 15, 2025
pulisher
May 15, 2025

Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World

May 15, 2025
pulisher
May 14, 2025

GSK’s liver asset play grows group of $1B upfront deals - biocentury.com

May 14, 2025
pulisher
May 14, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

May 13, 2025
pulisher
May 13, 2025

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World

May 13, 2025
pulisher
May 12, 2025

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 12, 2025
pulisher
May 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 12, 2025
pulisher
May 12, 2025

Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target - Investing.com

May 12, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 09, 2025
pulisher
May 09, 2025

BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st

May 09, 2025
pulisher
May 09, 2025

NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView

May 09, 2025
pulisher
May 09, 2025

BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

BTIG maintains Buy on Nektar stock, price target at $4.00 - Investing.com

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com

May 09, 2025
pulisher
May 09, 2025

Nektar: Q1 Earnings Snapshot - The Washington Post

May 09, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses E - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timel - GuruFocus

May 08, 2025

넥타테라퓨틱스 (NKTR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
자본화:     |  볼륨(24시간):